BI-9564 - BRD9 Bromodomain Inhibitor. CAS# 1883429-22-8 size:2 mg solid 5-naphthyridine derivatives as a novel

5-naphthyridine derivatives as a novel series of potent and selective TGF-beta type I receptor inhibitors

1 μM canertinib inhibits ErbB1-3 receptor phosphorylation with a concomitant decrease of Akt-

507: a subnanomolar human beta 3 adrenergic receptor agonist

Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b

(2014) J Immunother Cancer

BI-9564 - BRD9 Bromodomain Inhibitor. CAS# 1883429-22-8 size:2 mg solid 5-naphthyridine derivatives as a novelBI 9564, CAS No. 1883429 22 8, is a potent and selective inhibitor of BRD9 and BRD7 bromodomains (Kds = 14. 1 and 239 nM; IC50s = 75 nM and 3. 4 M, respectively). BI 9564 is useful in further exploring BRD9 bromodomain biology in both in vitro and in vivo settings. Selective inhibitors of bromodomain containing protein 9 (BRD9) may have therapeutic potential in the treatment of human malignancies and inflammatory diseases. Product information CAS